DK1513806T3 - Sulfonsyresalte af sulfonsyrederivater - Google Patents

Sulfonsyresalte af sulfonsyrederivater

Info

Publication number: DK1513806T3
Authority: DK; Denmark
Prior art keywords: sulfonic acid; acid derivatives; salts; acid salts; derivatives
Prior art date: 2002-05-31

Application number

DK03728206T

Other languages

English (en)

Inventor

Matti Ahlqvist

Anita Lundblad

Martin Bohlin

Tord Inghardt

Carl-Gustaf Sigfridsson

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-31

Filing date

2003-05-27

Publication date

2009-06-15

2003-05-27 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2009-06-15 Application granted granted Critical

2009-06-15 Publication of DK1513806T3 publication Critical patent/DK1513806T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

DK03728206T 2002-05-31 2003-05-27 Sulfonsyresalte af sulfonsyrederivater DK1513806T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0201661A SE0201661D0 (sv)	2002-05-31	2002-05-31	New salts
PCT/SE2003/000859 WO2003101957A1 (en)	2002-05-31	2003-05-27	New salts

Publications (1)

Publication Number	Publication Date
DK1513806T3 true DK1513806T3 (da)	2009-06-15

Family

ID=20288039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03728206T DK1513806T3 (da)	2002-05-31	2003-05-27	Sulfonsyresalte af sulfonsyrederivater

Country Status (30)

Country	Link
US (2)	US7273858B2 (da)
EP (2)	EP1513806B1 (da)
JP (1)	JP4541140B2 (da)
KR (1)	KR20050009726A (da)
CN (2)	CN1656067A (da)
AR (1)	AR039937A1 (da)
AT (1)	ATE425963T1 (da)
AU (1)	AU2003232871B2 (da)
BR (1)	BR0311365A (da)
CA (1)	CA2487509A1 (da)
CY (1)	CY1109085T1 (da)
DE (1)	DE60326720D1 (da)
DK (1)	DK1513806T3 (da)
ES (1)	ES2322048T3 (da)
IL (1)	IL165295A0 (da)
IS (1)	IS7598A (da)
MX (1)	MXPA04011912A (da)
MY (1)	MY133333A (da)
NO (1)	NO329064B1 (da)
NZ (2)	NZ536738A (da)
PL (1)	PL373794A1 (da)
PT (1)	PT1513806E (da)
RU (2)	RU2345064C2 (da)
SA (1)	SA03240440B1 (da)
SE (1)	SE0201661D0 (da)
SI (1)	SI1513806T1 (da)
TW (2)	TWI313173B (da)
UA (1)	UA81246C2 (da)
WO (1)	WO2003101957A1 (da)
ZA (1)	ZA200409228B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR035216A1 (es) *	2000-12-01	2004-05-05	Astrazeneca Ab	Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es)	2001-06-21	2004-02-25	Astrazeneca Ab	Formulacion farmaceutica
SE0201659D0 (sv)	2002-05-31	2002-05-31	Astrazeneca Ab	Modified release pharmaceutical formulation
SE0201661D0 (sv) *	2002-05-31	2002-05-31	Astrazeneca Ab	New salts
US7781424B2 (en) *	2003-05-27	2010-08-24	Astrazeneca Ab	Modified release pharmaceutical formulation
JP4550884B2 (ja) *	2004-04-09	2010-09-22	ハンミファーム．シーオー．，エルティーディー．	結晶性クロピドグレルナフタレンスルホン酸塩又はその水和物、その製造方法及びそれを含む医薬組成物
WO2005103059A1 (en) *	2004-04-20	2005-11-03	Sanofi-Aventis	Clopidogrel salt and polymorphic forms thereof
TW200827336A (en) *	2006-12-06	2008-07-01	Astrazeneca Ab	New crystalline forms
TW200900033A (en) *	2007-06-21	2009-01-01	Wen-Qing Li	Automatic brewing machine
US20090061000A1 (en) *	2007-08-31	2009-03-05	Astrazeneca Ab	Pharmaceutical formulation use 030

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU178398B (en) *	1979-06-12	1982-04-28	Gyogyszerkutato Intezet	Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en)	1981-03-11	1982-09-14	Kaken Pharmaceut Co Ltd	Slow-releasing pharmaceutical preparation
HU192646B (en)	1984-12-21	1987-06-29	Gyogyszerkutato Intezet	Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en)	1985-02-04	1991-11-21	Merrell Dow Pharma	Amino acid and peptide derivatives as peptidase inhibitors
US5187157A (en)	1987-06-05	1993-02-16	Du Pont Merck Pharmaceutical Company	Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) *	1987-07-28	1988-12-20	E. R. Squibb & Sons, Inc.	Controlled release formulation
EP0362002B1 (en)	1988-09-01	1995-07-26	Merrell Dow Pharmaceuticals Inc.	HIV protease inhibitors
ZA897514B (en)	1988-10-07	1990-06-27	Merrell Dow Pharma	Novel peptidase inhibitors
IT1229491B (it)	1988-12-28	1991-09-03	Roussel Maestretti S P A Ora R	Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (da)	1990-07-05	1993-03-01	Hoffmann La Roche
CA2075154A1 (en)	1991-08-06	1993-02-07	Neelakantan Balasubramanian	Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv)	1991-08-28	1991-08-28	Astra Ab	New isosteric peptides
US5169638A (en)	1991-10-23	1992-12-08	E. R. Squibb & Sons, Inc.	Buoyant controlled release powder formulation
CZ333492A3 (en)	1991-11-12	1993-09-15	Lilly Co Eli	Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv)	1991-12-04	1991-12-04	Astra Ab	New peptide derivatives
WO1993018060A1 (en)	1992-03-04	1993-09-16	Gyógyszerkutató Intézet Kft.	New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (da)	1992-03-06	1994-05-11	Hoffmann La Roche
SE9301912D0 (sv) *	1993-06-03	1993-06-03	Ab Astra	Process for the production of aminoalkylguandines
US6984627B1 (en) *	1993-06-03	2006-01-10	Astrazeneca Ab	Peptide derivatives
SE9301916D0 (sv) *	1993-06-03	1993-06-03	Ab Astra	New peptides derivatives
US5780631A (en) *	1993-06-03	1998-07-14	Astra Aktiebolag	Starting materials in the synthesis of thrombin and kininogenase inhibitors
EP0648780A1 (en)	1993-08-26	1995-04-19	Bristol-Myers Squibb Company	Heterocyclic thrombin inhibitors
TW394760B (en) *	1993-09-07	2000-06-21	Hoffmann La Roche	Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) *	1994-01-27	2010-03-09	Masahiro Ohshima	Prolineamide derivatives
US5707966A (en) *	1994-03-04	1998-01-13	Eli Lilly And Company	Antithrombotic agents
US5705487A (en) *	1994-03-04	1998-01-06	Eli Lilly And Company	Antithrombotic agents
IL112795A (en)	1994-03-04	2001-01-28	Astrazeneca Ab	Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5561146A (en)	1994-06-10	1996-10-01	Bristol-Myers Squibb Company	Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de)	1994-06-17	1995-12-21	Basf Ag	Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) *	1994-06-28	1996-03-12	Aktiebolaget Astra	Pyrazoleamidine compounds
US5510369A (en)	1994-07-22	1996-04-23	Merck & Co., Inc.	Pyrrolidine thrombin inhibitors
PL321759A1 (en) *	1995-02-17	1997-12-22	Basf Ag	Novel thrombosin inhibitors
US5710130A (en) *	1995-02-27	1998-01-20	Eli Lilly And Company	Antithrombotic agents
US5695781A (en)	1995-03-01	1997-12-09	Hallmark Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers
US6083532A (en)	1995-03-01	2000-07-04	Duramed Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO1996031504A1 (en)	1995-04-04	1996-10-10	Merck & Co., Inc.	Thrombin inhibitors
US5629324A (en)	1995-04-10	1997-05-13	Merck & Co., Inc.	Thrombin inhibitors
SA96170106A (ar) *	1995-07-06	2005-12-03	أسترا أكتيبولاج	مشتقات حامض أميني جديدة
TWI238827B (en) *	1995-12-21	2005-09-01	Astrazeneca Ab	Prodrugs of thrombin inhibitors
SE9601556D0 (sv)	1996-04-24	1996-04-24	Astra Ab	New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602263D0 (sv)	1996-06-07	1996-06-07	Astra Ab	New amino acid derivatives
AU3496297A (en)	1996-06-25	1998-01-14	Eli Lilly And Company	Anticoagulant agents
SE9602646D0 (sv)	1996-07-04	1996-07-04	Astra Ab	Pharmaceutically-useful compounds
DE19632772A1 (de)	1996-08-14	1998-02-19	Basf Ag	Neue Benzamidine
SE9603724D0 (sv)	1996-10-11	1996-10-11	Astra Ab	New pharmaceutical parenteral formulation of a thrombin inhibitor
AR013084A1 (es)	1997-06-19	2000-12-13	Astrazeneca Ab	Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it)	1997-10-29	1999-12-17	Ciocca Maurizio	Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv)	1997-12-05	1997-12-05	Astra Ab	New compounds
US6251430B1 (en)	1998-02-04	2001-06-26	Guohua Zhang	Water insoluble polymer based sustained release formulation
US6174913B1 (en) *	1998-06-05	2001-01-16	The University Of North Carolina At Chapel Hill	Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) *	1998-09-01	1998-09-01	Astra Ab	Improved stability for injection solutions
SE9802974D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	New crystalline forms
SE9802973D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	Immediate release tablet
PT1107791E (pt)	1998-09-04	2007-07-06	Scios Inc	Composições de hidrogel para a administração com libertação controlada de factores de crescimento
SE9804313D0 (sv)	1998-12-14	1998-12-14	Astra Ab	New compounds
CA2355792A1 (en) *	1999-01-13	2000-07-20	Astrazeneca Ab	New amidinobenzylamine derivatives and their use as thrombin inhibitors
SE9902550D0 (sv)	1999-07-02	1999-07-02	Astra Ab	New crystalline forms
SE0001803D0 (sv)	2000-05-16	2000-05-16	Astrazeneca Ab	New compounds i
ES2311538T3 (es) *	2000-08-16	2009-02-16	Astrazeneca Ab	Nuevos derivados amidino y su uso como inhibidores de trombina.
US6433186B1 (en) *	2000-08-16	2002-08-13	Astrazeneca Ab	Amidino derivatives and their use as thormbin inhibitors
SE0003125D0 (sv)	2000-09-05	2000-09-05	Astrazeneca Ab	Modified polymers
SE0102921D0 (sv) *	2001-08-30	2001-08-30	Astrazeneca Ab	Pharmaceutically useful compounds
AR035216A1 (es) *	2000-12-01	2004-05-05	Astrazeneca Ab	Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) *	2000-12-01	2006-10-31	Astrazeneca Ab	Mandelic acid derivatives and their use as thrombin inhibitors
US6287599B1 (en)	2000-12-20	2001-09-11	Shire Laboratories, Inc.	Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (es)	2001-06-21	2004-02-25	Astrazeneca Ab	Formulacion farmaceutica
UA78195C2 (uk)	2001-08-30	2007-03-15	Astrazeneca Ab	Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі
US6811794B2 (en)	2001-12-20	2004-11-02	Shire Laboratories, Inc.	Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201659D0 (sv)	2002-05-31	2002-05-31	Astrazeneca Ab	Modified release pharmaceutical formulation
SE0201661D0 (sv)	2002-05-31	2002-05-31	Astrazeneca Ab	New salts
SE0201658D0 (sv)	2002-05-31	2002-05-31	Astrazeneca Ab	Immediate release pharmaceutical formulation
US7781424B2 (en)	2003-05-27	2010-08-24	Astrazeneca Ab	Modified release pharmaceutical formulation
SE0303220D0 (sv)	2003-11-28	2003-11-28	Astrazeneca Ab	New process
GB0503672D0 (en)	2005-02-23	2005-03-30	Astrazeneca Ab	New process
GB0510546D0 (en)	2005-05-24	2005-06-29	Astrazeneca Ab	New process
TW200827336A (en)	2006-12-06	2008-07-01	Astrazeneca Ab	New crystalline forms

2002
- 2002-05-31 SE SE0201661A patent/SE0201661D0/xx unknown
2003
- 2003-05-27 WO PCT/SE2003/000859 patent/WO2003101957A1/en not_active Ceased
- 2003-05-27 CN CNA038124912A patent/CN1656067A/zh active Pending
- 2003-05-27 CA CA002487509A patent/CA2487509A1/en not_active Abandoned
- 2003-05-27 MX MXPA04011912A patent/MXPA04011912A/es active IP Right Grant
- 2003-05-27 AT AT03728206T patent/ATE425963T1/de not_active IP Right Cessation
- 2003-05-27 EP EP03728206A patent/EP1513806B1/en not_active Expired - Lifetime
- 2003-05-27 DE DE60326720T patent/DE60326720D1/de not_active Expired - Lifetime
- 2003-05-27 SI SI200331578T patent/SI1513806T1/sl unknown
- 2003-05-27 PL PL03373794A patent/PL373794A1/xx not_active Application Discontinuation
- 2003-05-27 AU AU2003232871A patent/AU2003232871B2/en not_active Ceased
- 2003-05-27 KR KR10-2004-7019439A patent/KR20050009726A/ko not_active Ceased
- 2003-05-27 RU RU2004133388/04A patent/RU2345064C2/ru not_active IP Right Cessation
- 2003-05-27 NZ NZ536738A patent/NZ536738A/en not_active IP Right Cessation
- 2003-05-27 UA UA20041109441A patent/UA81246C2/uk unknown
- 2003-05-27 CN CN200910260483A patent/CN101735131A/zh active Pending
- 2003-05-27 IL IL16529503A patent/IL165295A0/xx unknown
- 2003-05-27 US US10/516,422 patent/US7273858B2/en not_active Expired - Fee Related
- 2003-05-27 NZ NZ554323A patent/NZ554323A/en not_active IP Right Cessation
- 2003-05-27 PT PT03728206T patent/PT1513806E/pt unknown
- 2003-05-27 ES ES03728206T patent/ES2322048T3/es not_active Expired - Lifetime
- 2003-05-27 BR BR0311365-5A patent/BR0311365A/pt not_active IP Right Cessation
- 2003-05-27 EP EP09151657A patent/EP2055696A1/en not_active Withdrawn
- 2003-05-27 JP JP2004509651A patent/JP4541140B2/ja not_active Expired - Fee Related
- 2003-05-27 DK DK03728206T patent/DK1513806T3/da active
- 2003-05-29 MY MYPI20031981A patent/MY133333A/en unknown
- 2003-05-30 TW TW092114807A patent/TWI313173B/zh active
- 2003-05-30 AR ARP030101935A patent/AR039937A1/es unknown
- 2003-05-30 TW TW097151265A patent/TWI367754B/zh not_active IP Right Cessation
- 2003-12-10 SA SA3240440A patent/SA03240440B1/ar unknown
2004
- 2004-11-09 NO NO20044867A patent/NO329064B1/no not_active IP Right Cessation
- 2004-11-17 ZA ZA200409228A patent/ZA200409228B/en unknown
- 2004-12-15 IS IS7598A patent/IS7598A/is unknown
2007
- 2007-08-16 US US11/839,842 patent/US7763597B2/en not_active Expired - Fee Related
2008
- 2008-07-09 RU RU2008127541/04A patent/RU2008127541A/ru not_active Application Discontinuation
2009
- 2009-05-20 CY CY20091100535T patent/CY1109085T1/el unknown

Also Published As

Publication number	Publication date
NZ536738A (en)	2007-05-31
CY1109085T1 (el)	2012-05-23
JP2005532346A (ja)	2005-10-27
RU2345064C2 (ru)	2009-01-27
ATE425963T1 (de)	2009-04-15
EP2055696A1 (en)	2009-05-06
US7763597B2 (en)	2010-07-27
US20080269176A1 (en)	2008-10-30
TWI367754B (en)	2012-07-11
RU2008127541A (ru)	2010-01-20
DE60326720D1 (de)	2009-04-30
UA81246C2 (en)	2007-12-25
ZA200409228B (en)	2005-05-17
US7273858B2 (en)	2007-09-25
TW200927094A (en)	2009-07-01
EP1513806B1 (en)	2009-03-18
IL165295A0 (en)	2005-12-18
NO329064B1 (no)	2010-08-09
PL373794A1 (en)	2005-09-19
EP1513806A1 (en)	2005-03-16
AU2003232871B2 (en)	2010-08-19
NO20044867L (no)	2004-12-23
TW200402293A (en)	2004-02-16
RU2004133388A (ru)	2005-07-10
AU2003232871A1 (en)	2003-12-19
SA03240440B1 (ar)	2008-02-24
AR039937A1 (es)	2005-03-09
TWI313173B (en)	2009-08-11
CN101735131A (zh)	2010-06-16
WO2003101957A1 (en)	2003-12-11
JP4541140B2 (ja)	2010-09-08
HK1073102A1 (en)	2005-09-23
US20050234035A1 (en)	2005-10-20
SI1513806T1 (sl)	2009-06-30
BR0311365A (pt)	2005-03-01
PT1513806E (pt)	2009-05-04
SE0201661D0 (sv)	2002-05-31
CA2487509A1 (en)	2003-12-11
KR20050009726A (ko)	2005-01-25
MXPA04011912A (es)	2005-03-31
NZ554323A (en)	2008-10-31
IS7598A (is)	2004-12-15
CN1656067A (zh)	2005-08-17
ES2322048T3 (es)	2009-06-16
MY133333A (en)	2007-11-30

Publication	Publication Date	Title
IS7818A (is)	2005-04-22	Tafin losun á amfetamínsöltum
CY2009011I1 (el)	2010-07-28	Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
DK1485365T3 (da)	2008-09-01	Sulfonyl-derivater som nye inhibitorer af histandeacetylase
DK1802579T3 (da)	2014-01-20	Derivater af 3-arylaminopyridin
DK1360169T3 (da)	2007-11-26	Succinatsalt af O-desmethyl-venlafaxin
DK1648889T3 (da)	2009-01-05	Isethionatsalt af en selektiv CDK4-inhibitor
DK1562902T3 (da)	2006-08-14	2-pyridonderivater som inhibitorer af neutrofilelastase
EP1674473A4 (en)	2008-12-17	Photoacid generator
IS6987A (is)	2003-10-09	Nýjar súlfónsýru afleiður
ATE427296T1 (de)	2009-04-15	Phenoxyessigsaurederivate
IS8348A (is)	2006-03-09	Samrunnin heteróhringasambönd
DK1341779T3 (da)	2006-10-30	Heterocyklisk sulfonamid-inhibitorer af beta-amyloidproduktion
ATE438628T1 (de)	2009-08-15	Pyridazinderivate
DK1501508T3 (da)	2007-05-21	Inhibitorer af histondeatylase
DK1622612T3 (da)	2008-05-26	Farmaceutisk formulering af natriumsaltet af telmitarsan
ATE504588T1 (de)	2011-04-15	Stabile salze von olanzapin
DK1410793T3 (da)	2006-04-03	Administreringsform af ibuprofen-natrium
DK1401828T3 (da)	2006-07-31	N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DK1516540T3 (da)	2012-11-26	Anvendelse af vitamin D-forbindelser
DK1442023T3 (da)	2007-11-05	Krystallinsk natriumsalt af telmisartan og anvendelse af dette som angiotensinantagonist
DK1600441T3 (da)	2010-02-08	Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel
DK1513806T3 (da)	2009-06-15	Sulfonsyresalte af sulfonsyrederivater
DK1377544T3 (da)	2014-08-11	Oprensning af 2-nitro-4-methylsulfonylbenzoesyre
DK1519928T3 (da)	2014-08-04	Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DK1556026T3 (da)	2009-08-24	Hidtil ukendt farmaceutiske formuleringer af modafinil